AAAAAA
Results:
1-7
|
Results: 7
Authors:
Lee, CW
Weir, L
Gelmon, KA
Citation: Cw. Lee et al., Effect of news media coverage of cancer risk on clinical oncology practice, J NAT CANC, 93(21), 2001, pp. 1656-1657
Authors:
Gelmon, KA
Latreille, J
Tolcher, A
Genier, L
Fisher, B
Forand, D
D'Aloisio, S
Vernillet, L
Daigneault, L
Lebecq, A
Besenval, M
Eisenhauer, E
Citation: Ka. Gelmon et al., Phase I dose-finding study of a new taxane, RPR 109881A, administered as aone-hour intravenous infusion days 1 and 8 to patients with advanced solidtumors, J CL ONCOL, 18(24), 2000, pp. 4098-4108
Authors:
Gelmon, KA
Eisenhauer, EA
Harris, AL
Ratain, MJ
Workman, P
Citation: Ka. Gelmon et al., Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?, J NAT CANC, 91(15), 1999, pp. 1281-1287
Authors:
Tolcher, AW
Sugarman, S
Gelmon, KA
Cohen, R
Saleh, M
Isaacs, C
Young, L
Healey, D
Onetto, N
Slichenmyer, W
Citation: Aw. Tolcher et al., Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, J CL ONCOL, 17(2), 1999, pp. 478-484
Authors:
Gelmon, KA
Tolcher, A
Diab, AR
Bally, MB
Embree, L
Hudon, N
Dedhar, C
Ayers, D
Eisen, A
Melosky, B
Burge, C
Logan, P
Mayer, LD
Citation: Ka. Gelmon et al., Phase I study of liposomal vincristine, J CL ONCOL, 17(2), 1999, pp. 697-705
Authors:
Gelmon, KA
Tolcher, A
O'Reilly, S
Campbell, C
Bryce, C
Shenkier, T
Ragaz, J
Ayers, D
Nakashima, L
Rielly, S
Dulude, H
Citation: Ka. Gelmon et al., A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer, ANN ONCOL, 9(11), 1998, pp. 1247-1249
Authors:
Latreille, J
Gelmon, KA
Hirsh, V
Laberge, F
Maksymiuk, AW
Shepherd, FA
Delorme, F
Berille, J
Citation: J. Latreille et al., Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience, INV NEW DR, 16(3), 1998, pp. 265-270
Risultati:
1-7
|